Clinical Trials Browser

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 2/3 Completed

196 enrolled 31 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03410615 2026-01-14

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Phase 2 Active not recruiting

129 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Phase 1 Completed

19 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03635164 2025-06-27

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Phase 1 Completed

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Completed

38 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

54 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT03726775 2025-05-07

REWRITe

Phase 2 Active not recruiting

61 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02827838 2025-03-17

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Phase EARLY_PHASE1 Terminated

17 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT03509012 2025-01-14

CLOVER

Phase 1 Completed

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03784066 2024-07-03

DUTRELASCO

Phase 1/2 Active not recruiting

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03283605 2024-06-28

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Phase 1/2 Active not recruiting

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06446570 2024-06-06

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Phase 2 Completed

18 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

Phase 2 Completed

104 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

340 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03624231 2023-08-31

DURTRE-RAD

Phase 2 Completed

18 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03292250 2022-03-29